The estimated Net Worth of Betty D Larson is at least $3.88 Миллион dollars as of 25 February 2022. Ms. Larson owns over 46,658 units of Becton Dickinson & Co stock worth over $2,233,142 and over the last 8 years she sold BDX stock worth over $1,645,064. In addition, she makes $0 as Executive Vice President- Human Resources и Chief Human Resources at Becton Dickinson & Co.
Sign up
Ms. Larson BDX stock SEC Form 4 insiders trading
Betty has made over 7 trades of the Becton Dickinson & Co stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 46,658 units of BDX stock worth $8,776,836 on 25 February 2022.
The largest trade she's ever made was exercising 46,658 units of Becton Dickinson & Co stock on 25 February 2022 worth over $8,776,836. On average, Betty trades about 2,482 units every 66 days since 2016. As of 25 February 2022 she still owns at least 9,556 units of Becton Dickinson & Co stock.
You can see the complete history of Ms. Larson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Betty Larson biography
Betty D. Larson serves as Executive Vice President- Human Resources, Chief Human Resources of the Company. She was Vice President of Human Resources, Interventional Segment from December 2017 to July 2018; Vice President, Human Resources, C.R. Bard, Inc. from September 2014 to December 2017; and prior thereto, Vice President, Human Resources - Global Medical Products Business, Baxter International.
How old is Betty Larson?
Betty Larson is 43, she's been the Executive Vice President- Human Resources и Chief Human Resources of Becton Dickinson & Co since 2018. There are 32 older and 1 younger executives at Becton Dickinson & Co. The oldest executive at Becton Dickinson & Co. is Marshall Larsen, 71, who is the Lead Independent Director.
What's Betty Larson's mailing address?
Betty's mailing address filed with the SEC is 126 EAST LINCOLN AVENUE, , RAHWAY, NJ, 07065.
Insiders trading at Becton Dickinson & Co
Over the last 22 years, insiders at Becton Dickinson & Co have traded over $106,782,599 worth of Becton Dickinson & Co stock and bought 23,860 units worth $1,771,828 . The most active insiders traders include Edward J Ludwig, William M Brown и Vincent A Forlenza. On average, Becton Dickinson & Co executives and independent directors trade stock every 20 days with the average trade being worth of $4,349,205. The most recent stock trade was executed by Roland Goette on 14 August 2024, trading 5,295 units of BDX stock currently worth $701,799.
What does Becton Dickinson & Co do?
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.
What does Becton Dickinson & Co's logo look like?
Complete history of Ms. Larson stock trades at Becton Dickinson & Co и Merck & Co Inc
Becton Dickinson & Co executives and stock owners
Becton Dickinson & Co executives and other stock owners filed with the SEC include:
-
Vincent Forlenza,
Executive Chairman of the Board -
Patrick Kaltenbach,
Executive Vice President, President - Life Sciences -
Thomas Polen,
President, Chief Executive Officer, Chief Operating Officer, Director -
Christopher Reidy,
Chief Financial Officer, Executive Vice President, Chief Administrative Officer -
Alberto Mas,
Executive Vice President, President - Medical Segment -
Thomas E. Polen Jr.,
Pres, CEO & Chairman -
Samrat Khichi,
Executive Vice President - Public Policy and Regulatory Affairs -
Alexandre Conroy,
Executive Vice President, Chief Integrated Supply Chain Officer -
Vincent A. Forlenza,
Exec. Chairman -
Samrat S. Khichi,
Exec. VP of Regulatory & Gov. Affairs and Gen. Counsel -
Alberto Mas,
Exec. VP & Pres of the Medical Segment -
Samrat S. Khichi Esq.,
Exec. VP of Corp. Devel., Public Policy & Regulatory Affairs and Gen. Counsel -
Christopher R. Reidy,
Exec. VP, CFO & Chief Admin. Officer -
Simon D. Campion,
Exec. VP & Pres of Interventional Segment -
Christopher DelOrefice,
Exec. VP & CFO -
Marshall Larsen,
Lead Independent Director -
Bertram Scott,
Independent Director -
Claire Fraser,
Independent Director -
Christopher Jones,
Independent Director -
Catherine Burzik,
Independent Director -
Claire Pomeroy,
Independent Director -
Timothy Ring,
Independent Director -
Rebecca Rimel,
Independent Director -
David Melcher,
Independent Director -
Jeffrey Henderson,
Independent Director -
R. Andrew Eckert,
Independent Director -
John DeFord,
Executive Vice President, Chief Technology Officer -
James Lim,
Executive Vice President, President, Greater Asia -
Thomas Spoerel,
Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller -
Monique Dolecki,
Investor Relations Contact Officer -
Charles Bodner,
Senior Vice President, Corporate Finance -
Roland Goette,
Executive Vice President, President - EMEA -
Simon Campion,
Executive Vice President and President, BD Interventional Segment -
Betty Larson,
Executive Vice President- Human Resources, Chief Human Resources -
Denise Fleming,
Exec. VP of Technology & Global Services and Chief Information Officer -
Francesca M. DeMartino,
Sr. VP of Investor Relations -
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.,
Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board -
Troy Kirkpatrick,
VP of PR -
Elizabeth McCombs,
Exec. VP & Chief Technology Officer -
Michelle Quinn,
Sr. VP and Chief Ethics & Compliance Officer -
Jerry Flasz,
Exec. VP of Global Services & Chief Information Officer -
Dr. John A. DeFord,
Exec. VP of R&D and CTO -
Thomas J. Spoerel,
Sr. VP, Controller & Chief Accounting Officer -
Joanne Waldstreicher,
Director -
Gary A Mecklenburg,
Director -
John E Gallagher,
VP, Corp Finance and Treasurer -
Linda M Tharby,
Segment Pres. Life Sciences -
Wilard J Jr Overlock,
Director -
Nabil Shabshab,
Senior Vice President -
Jeffrey S Sherman,
VP and General Counsel -
Basil Anderson,
Director -
Ellen R Strahlman,
Senior Vice President -
James F Orr,
Director -
William A Tozzi,
VP and Controller -
Gary M Cohen,
President - BD Medical Systems -
Stephen Sichak,
Senior Vice President -
Henry P Jr Becton,
Director -
Carrie L Byington,
Director -
Edward Degraan,
Director -
William A Kozy,
Pres - BD CLS and Cmpy Oper -
Alfred Sommer,
Director -
David Shan,
EVP and Chief ISC Officer -
Shana Carol Neal,
EVP and Chief People Officer -
John P Groetelaars,
EVP -
James W Borzi,
EVP & Chief Supply Chain Offcr -
Suketu Upadhyay,
Senior VP and Controller -
Adel Mahmoud,
Director -
Jerome V Hurwitz,
Senior Vice President -
Donna M Boles,
Sr. Exec VP - Human Resources -
David V Elkins,
Executive VP and CFO -
David T Durack,
Senior Vice President -
William E. Rhodes,
Senior Vice President -
Joseph Mercurio,
VP and Corporate Controller -
Patricia B Shrader,
Senior Vice President -
Scott P Bruder,
SrVP; Chief Technology Officer -
Cathy E. Minehan,
Director -
Margeretha Af Ugglas,
Director -
Edward J Ludwig,
Chairman, President and CEO -
James E Perrella,
Director -
Alfred John Hanson,
Executive Vice President -
John R Considine,
Executive VP and CFO -
Jean Marc Dageville,
VP - Human Resources -
Harry N Beaty,
Director -
Frank Albert Olson,
Director -
Bridget M Healy,
VP, Gen Counsel and Secy -
Christopher Del Orefice,
EVP & Chief Financial Officer -
Antoine C Ezell,
EVP, President NA & CMO -
David Hickey,
EVP & President, Life Sciences -
William M Brown,
Director -
Rishi Grover,
EVP and Chief ISC Officer -
Michael David Garrison,
EVP & President Medical -
Richard Byrd,
EVP & President Interventional -
Pavan Kumar Mocherla,
EVP & President Greater Asia -
Michael Feld,
EVP & President, Life Sciences